Advertisement

Archives of Pharmacal Research

, Volume 30, Issue 2, pp 222–234 | Cite as

Preparation,In vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac

  • S. Mutalik
  • A. Naha
  • A. N. Usha
  • A. K. Ranjith
  • P. Musmade
  • K. Manoj
  • P. Anju
  • S. Prasanna
Article Drug efficacy

Abstract

The objective of the present study was to develop“once daily” sustained release tablets of aceclofenac by direct compression using hydroxypropyl methylcellulose-K4M (HPMC). The solubility studies of aceclofenac were conducted to select suitable dissolution media. The drug-excipient mixtures were subjected to preformulation studies. The tablets were subjected to physicochemical,in vitro drug release and stability studies. Preclinical (anti-inflammatory, analgesic, pharmacokinetic and toxicity studies) and clinical pharmacokinetic studies were conducted for optimized tablets. Based on the preformulation results, microcrystalline cellulose (MCC), dicalcium phosphate and spray dried lactose (SDL) were selected as directly compressible vehicles. Because of the incompatibility with aceclofenac, SDL was excluded from the study. The physicochemical properties of tablets were found within the limits. By comparing the dissolution profiles with the marketed product, the tablet containing HPMC (45%) and MCC (30%) along with talc and magnesium stearate (1% w/w, each) (Tablet B7) was considered as a better formulation. This tablet exhibited almost similar drug release profile in different dissolution media as that of marketed tablet. Tablet B7 was stable in accelerated conditions for 6 months. The composition of this tablet showed almost similar preclinical pharmacological activities compared to marketed tablet composition and did not exhibit any toxicity in rats and mice with respect to tested haematological and biochemical parameters along with body weight, food and water intake. The pharmacokinetic study in healthy human volunteers indicated that B7 tablet produced an extended drug release of drug upto 24 h as that of marketed product with almost identical pharmacokinetic parameters.

Key words

Aceclofenac Sustained release Once daily Matrix tablets Hydroxypropyl methyl-cellulose Direct compression Pharmacokinetics Analgesic Anti-inflammatory Toxicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alderman, D. A., A review of cellulose ethers in hydrophilic matrices for oral controlled dosage forms.Int. J. Pharm. Tech. Prod. Manul, 3,1–9 (1984).Google Scholar
  2. Amaral, M. H., Lobo, J. M., and Ferreira, D. C, Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets. AAPS. PharmSciTech., 2, article 6:1–8, (2001).Google Scholar
  3. Aulton, E. M., Pharmaceutics-The Science of Dosage Form Design. ELBS/Churchill Livingstone, London, (1990).Google Scholar
  4. British Pharmacopoeia.The Stationary office, MHRA, British Pharmacopoeial Commission office, Vol. 1, London, (dy2005).Google Scholar
  5. Chien, Y. W., Regulatory considerations in controlled release medication, In Chien, Y W. (Eds). Novel Drug Delivery Systems. Marcel Dekker, New York, pp. 577–578, (1982).Google Scholar
  6. Ford, J. L, Rubinstein, M. H., and Hogan, J. E., Formulation of sustained-release promethazine hydrochloride tablets using hydroxypropyl methylcellulose matrices.Int. J. Pharm., 24, 327–338(1985).CrossRefGoogle Scholar
  7. Indian Pharmacopoeia, Ministry of Health and Family Welfare, Government of India, Controller of Publications, Vol. 2, Delhi, (1996).Google Scholar
  8. Kay, A. E. and Alldred, A., Rheumatoid Arthritis and Osteoarthritis, In Walker, R., Edwards, C, (ed.) Clinical Pharmacy and Therapeutics, 3rd ed., Churchill Livingstone, London, pp. 791–807, (2003).Google Scholar
  9. Kuksal, A., Tiwary, A. K., Jain, N. K., and Jain, S., Formulation andIn Vitro, In Vivo Evaluation of Extendedrelease Matrix Tablet of Zidovudine: Influence of Combination of Hydrophilic and Hydrophobic Matrix Formers. AAPS. PharmSciTech., 1, Article 1: 1–9,(2006).CrossRefGoogle Scholar
  10. Kulkami, S.K., Handbook of experimental pharmacology, 2nd edn., Vallabh Prakashan, New Delhi, (1997).Google Scholar
  11. Liebermann, H. A., Lachman, L., and Schwartz, J. B., Pharmaceutical Dosage Forms: Tablets, Vol. 2, Marcel Dekker, New York, pp. 201–243, (1990).Google Scholar
  12. Lordi, G. N., Sustained release dosage forms, In Lachman, L., Lieberman, H. A., Kanig, J. L., (ed.) The Theory and Practice of Industrial Pharmacy, 3rd ed., Varghese Publishing House, New Delhi, pp. 442–454, (1991).Google Scholar
  13. Mahaguna, V, Talbert, R. L, Peters, J. I., Adams, S., Reynolds, T. D., and Lam, F. Y W., Influence of hydroxypropyl methyl-cellulose polymer onin vitro andin vivo performance of controlled release tablets containing alprazolam.Eur. J. Pharm. Biopharm., 56, 461–468, (2003).PubMedCrossRefGoogle Scholar
  14. Mutalik, S. and Hiremath, D., Formulation and evaluation of chitosan matrix tablets of nifedipine.The Eastern. Pharmacist., 10,109–111,(2000).Google Scholar
  15. Mutalik, S., Paridhavi, K., Rao, M., and Udupa, N., Analgesic and antipyretic effect ofSolanum melongena.Indian J. Pharmacol., 32, 312–315 (2003a).Google Scholar
  16. Mutalik, S., Sulochana, B., Chetana, M., Udupa, N., and Uma Devi, P., Preliminary studies on acute and subacute toxicity studies of an antidiabetic herbal formulation, Dianex.Indian J. Exptl. Bid., 4, 316–320 (2003b).Google Scholar
  17. Mutalik, S. and Udupa, N., Formulation development,in vitro andin vivo evaluation of membrane controlled transdermal systems of glibenclamide.J. Pharm. Pharmaceut. Sci., 1, 26–38 (2005).Google Scholar
  18. Nellore, R. V, Rekhi, G. S., Hussain, A. S., Tillman, L. G, and Augsburger, L. L., Development of metoprolol tartrate extended-release matrix tablet formulations for regulatory policy consideration.J. Controlled. Rel., 50, 247–256, (1998).CrossRefGoogle Scholar
  19. Parfitt, K., Analgesics Anti-inflammatory and antipyretics, In Reynolds, J. E. F., (ed.) Martindale: The Complete Drug Reference, 32nd ed., Massachusetts, pp. 2-12, (1999).Google Scholar
  20. Reddy, R., Mutalik, S., and Reddy, M. S., Once daily sustained release matrix tablets of nicorandil: Formulation and in vitro evaluation. AAPS. PharmSciTech., 4, Article 61:1–9, (2003).Google Scholar
  21. Terashita, K. and Imamura, K., Preparation of antipyretic analgesic by direct compression and its evaluation.Chem. Pharm. Bull., 12,1542–1549, (2002).CrossRefGoogle Scholar
  22. Vueba, M. L, Batista, D. C, Veiga, F., Sousa, J. J., and Pina, M. E., Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets.Eur. J. Pharm. Biopharm., 1,51–59(2004).CrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2007

Authors and Affiliations

  • S. Mutalik
    • 2
  • A. Naha
    • 2
  • A. N. Usha
    • 2
  • A. K. Ranjith
    • 2
  • P. Musmade
    • 2
  • K. Manoj
    • 2
  • P. Anju
    • 2
  • S. Prasanna
    • 1
  1. 1.Formulation Development DepartmentExela Pharm SciBangaloreKamataka, India
  2. 2.Department of PharmaceuticsManipal College of Pharmaceutical SciencesManipal 576 104, Kamataka StateIndia, Kamataka

Personalised recommendations